MedTrace Logo

Characterizing the Incretin Effect of Amino Acids and Defining GLP-1 Role on Skeletal Muscle

NCT02370745 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-05-02

No results posted yet for this study

Summary

This study has two protocols the aims of which are:

1. To identify age-related effects of AA on incretin secretion and whether and to what extent AA exhibit a true incretin effect (gut- mediated increases in plasma insulin) in younger individuals. (Protocol 1)
2. To define the extra-pancreatic ''novel'', insulin independent effects of glucagon like peptide-1 (GLP-1) on postprandial muscle protein and glucose metabolism and microvascular blood flow. (Protocol 2)

Conditions

Interventions

DRUG

GLP-1

GLP-1 effects on skeletal muscle glucose and amino acid metabolism and microvascular blood flow will be scrutinised under the specified insulin concentrations. It will also be used to test the effect of intravenous feed on insulin secretion.

DRUG

Insulin Actrapid

Skeletal muscle metabolic and microvascular parameters will be tested under specified insulin concentrations with or without GLP-1

DIETARY_SUPPLEMENT

Oral amino acids

Oral amino acids containing 15 g of amino acids

DRUG

GIP

This will be co infused with GLP-1 and intravenous amino acids

DRUG

Intravenous amino acids

This will aim to deliver iso equivalent amount to the amino acids administered orally

Sponsors & Collaborators

  • University of Nottingham

    lead OTHER

Principal Investigators

  • Philip Atherton, PhD · University of Nottingham

  • Iskandar Idris, DM, FRCP · University of Nottingham

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02370745 on ClinicalTrials.gov